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PURPOSE. To investigate the effect of various riboflavin/ultraviolet light (UVA) crosslinking
(CXL) protocols on corneal enzymatic resistance.
METHODS. A total of 66 enucleated porcine eyes, with the corneal epithelium removed, were
divided into 6 groups. Group 1 remained untreated. Groups 2 to 6 received riboflavin/dextran
for 30 minutes. Group 3 underwent standard CXL (SCXL) with 3 mW/cm2 UVA for 30 minutes
(total energy dose 5.4 J/cm2). Groups 4 and 5 underwent high intensity CXL (HCXL) using 30
mW/cm2 UVA for 3 minutes (5.4 J/cm2) and 30 mW/cm2 for 4 minutes (7.2 J/cm2),
respectively. Group 6 was exposed to 8 minutes of 30 mW/cm2 UVA in a 10-second on/10-
second off pulsed-radiation mode (p-HCXL; 7.2 J/cm2). A central 8-mm disk from each cornea
was submerged in pepsin digest solution at 238C and measured daily. After 13 days, the dry
weight was recorded from 5 samples in each group.
RESULTS. The CXL-treated corneas took longer to digest than nonirradiated corneas (P <
0.0001). Differences in digestion time also were observed between CXL groups, such that,
HCXL (5.4 J/cm2) < SCXL (5.4 J/cm2) < HCXL (7.2 J/cm2) < p-HCXL (7.2 J/cm2; P < 0.0001).
The dry weight of the SCXL (5.4 J/cm2) group was higher than the HCXL (5.4 and 7.2 J/cm2; P
< 0.001) and p-HCXL 7.2 J/cm2 (P <0.05) groups. No difference was detected between the
HCXL and p-HCXL 7.2 J/cm2 groups.
CONCLUSIONS. The intensity and distribution of the crosslinks formed within the cornea vary
with different UVA protocols. The precise location and amount of crosslinking needed to
prevent disease progression is unknown.
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Keratoconus is a degenerative corneal dystrophy, character-ized by progressive corneal thinning and subsequent
impairment of corneal biomechanics.1–3 The resultant conical
ectasia causes irregular astigmatism and associated reduction of
visual performance, which can be significant.4 It typically
presents in adolescence and is the most common of all corneal
dystrophies with a reported incidence of 1 in 1750.1–3 Its
precise pathophysiology is as yet undetermined, but it has been
shown to be associated with an upregulation of degradative
proteolytic enzymes.5 Riboflavin and ultraviolet A (UVA)
corneal crosslinking (CXL) was first postulated in 1998 as a
means of strengthening the corneal stroma, increasing its
resistance to enzymatic digestion and stabilizing cases of
progressive keratoconus.6 It has since been the subject of a
plethora of research articles investigating and confirming its
safety and efficacy.7–10
The standard CXL protocol (SCXL), first clinically tested by
Wollensak et al.,8 involves removing the central 9 mm of
corneal epithelium, soaking the exposed stromal surface with
0.1% riboflavin for 30 minutes, and irradiating the riboflavin-
laden stroma with 370 nm UVA light with an intensity of 3 mW/
cm2 (resulting in a cumulative dose of 5.4 J/cm2). This protocol
requires in excess of 1 hour of treatment time. Given its
frequency of occurrence, the potential numbers of patients
with progressive keratoconus requiring CXL is large and
represents a not inconsiderable burden to health services. In
an attempt to reduce the treatment time, a number of
modifications to the existing SCXL protocol have been
proposed. These changes are based primarily on current
understanding of the photochemical kinetics of UVA exposure
and the theoretical principles of the Bunsen–Roscoe law of
reciprocity,11 which states that a certain biological effect is
directly proportional to the total energy dose irrespective of the
administered regimen. However, as has been shown with other
photochemical reactions,12 this law may only be valid within a
certain dose range and this must be defined individually for
each reaction.
The precise photochemical mechanism involved in ribofla-
vin/UVA CXL currently is uncertain. What has been shown,
however, is that oxygen is essential to drive the process and in
the absence of oxygen, CXL is impaired.13 It has been suggested
that higher intensity UVA, or so-called ‘‘accelerated’’ CXL
protocols, result in more rapid oxygen depletion thereby
reducing efficacy.14,15 It has been shown that by ceasing UV
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irradiation, oxygen can be restored to its normal level within 3
to 4 minutes16 and, on this basis, it has been proposed that by
pulsing the UV light throughout the procedure, oxygen levels
may be replenished so that the CXL process is no longer
impaired.17,18 In addition to pulsing, it also has been suggested
that the efficacy of accelerated protocols may be improved by
increasing the exposure time by 30% to 40%.19,20
To further investigate these issues and compare the efficacy
of accelerated CXL, extended accelerated CXL and pulsed CXL
protocols with the ‘‘gold standard’’ SCXL protocol, we
analyzed the rate of enzymatic digestion after CXL in an ex
vivo porcine model.
METHODS
Study Design
A total of 66 fresh porcine eyes, with transparent corneas and
an intact corneal epithelium, were obtained from a local
European Community licensed abattoir and used within 6
hours of death. Following a complete debridement of the
corneal epithelium using a single-edged razor blade, the eyes
were divided randomly and equally into the 6 groups described
below (in which Groups 1 and 2 served as controls).
1. Untreated (U): no treatment performed.
2. Riboflavin only (R): a 0.1% riboflavin solution containing
20% dextran T-500 (Mediocross D; Peschke Meditrade,
Huenenberg, Switzerland) was applied to the anterior
corneal surface for 30 minutes using an annular suction
ring.
3. Standard low-intensity CXL (SCXL 5.4 J/cm2): a 0.1%
riboflavin solution containing 20% dextran T-500 was
applied to the anterior corneal surface for 30 minutes (as
above). The cornea then was exposed to 3 mW UVA for
30 minutes (total energy dose of 5.4 J/cm2) during
which time riboflavin was reapplied at 5-minute
intervals.
4. High intensity 30 mW/3 min CXL (HCXL 5.4 J/cm2): a
0.1% riboflavin solution containing 20% dextran T-500
was applied to the anterior corneal surface for 30
minutes. The cornea then was exposed to 30 mW UVA
for a period of 3 minutes (total energy dose of 5.4 J/cm2)
during which time riboflavin was reapplied once.
5. High intensity 30 mW/4 min CXL (HCXL 7.2J/cm2): a
0.1% riboflavin solution containing 20% dextran T-500
was applied to the anterior corneal surface for 30
minutes. The cornea then was exposed to 30 mW UVA
for a period of 4 minutes (total energy dose of 7.2 J/cm2)
during which time riboflavin was reapplied once.
6. High intensity 30 mW/8min pulsed CXL (p-HCXL7.2 J/
cm2): a 0.1% riboflavin solution containing 20% dextran
T-500 was applied to the anterior corneal surface for 30
minutes. The cornea then was exposed to 30 mW UVA
in a pulsed radiation mode of 10 seconds on and 10
seconds off for a period of 8 minutes (total energy dose
of 7.2 J/cm2). During irradiation the riboflavin solution
was reapplied twice.
All of the irradiation protocols were performed using the
Phoenix CXL System (Peschke Meditrade) with a wavelength of
365 nm, a 50 mm working distance, and a 9 mm aperture.
Central corneal thickness was measured via ultrasound
pachymetry (DGH Pachmate 55; DGH Technologies, Exton,
PA, USA) before treatment (after epithelial debridement), after
riboflavin application, and after UVA exposure.
Following treatment, an 8 mm full-tissue-thickness biopsy
was trephined from the center of each cornea. The corneal
disks were placed in individual sealed tubes containing 5 mL
pepsin digest solution (1 g 600 to 1200 U/mg pepsin from
porcine gastric mucosa [Sigma-Aldrich, Dorset, UK] in 10 mL
0.1 M HCL at pH 1.2) and incubated in a water bath at 238C. As
our previous studies suggest that CXL causes the formation of
crosslinks not only at the collagen fibril surface but also in the
protein network surrounding the collagen,21 pepsin was
selected in preference to collagenase as the enzyme of choice
for this study.
Using electronic digital calipers, the diameter of the anterior
surface of each corneal disk was recorded daily until the tissue
could no longer be distinguished from the surrounding pepsin
solution (even under microscopic examination). At this point
the tissue was considered to have undergone ‘‘complete
digestion.’’ We recorded the daily diameter of the trephined
corneal disks, rather than corneal thickness, as corneal disks
placed in pepsin are known to undergo significant stromal
swelling (predominantly in the posterior stroma) during the
first 24 hours.22
To assess further the effect of each treatment on enzymatic
resistance, 5 corneal disks from each group were removed
from the pepsin digest solution after 13 days and placed in a
608C oven until a constant dry weight was obtained. The
average corneal dry weight then was calculated for each group.
The corneal disk diameter measurements provide valuable
information about the structural integrity of the most anterior
layers of the cornea, while the dry weight measurements,
representing the total mass of undigested tissue, negate the
complications associated with within-sample variations in
corneal thickness and between sample differences in hydration
and provide information about the effective depth of CXL.
Data Analysis
Data are shown as mean measurements (6SD) for corneal
thickness, dry weight, and complete digestion time. Measure-
ments of corneal disk diameter are presented as a daily
cumulative measurement for each treatment group. Statistical
analysis was performed using a one-way ANOVA and Bonferro-
ni multiple comparisons in a depth-wise manner. All statistical
analyses were performed with the Statistical Package for the
Social Sciences (SPSS Statistics 20; IBM, Armonk, NY, USA). A
probability value of P < 0.05 was considered significant.
RESULTS
Corneal Thickness
The average stromal thickness at each stage of treatment is
shown in Figure 1. Before treatment, the average stromal
thickness did not differ significantly between groups. However,
a 30-minute application of riboflavin–dextran solution (groups
2–6) resulted in a significant decrease in stromal thickness (P <
0.0001). The subsequent irradiation of corneas in groups 3 to 6
produced no further changes in corneal thickness and the final
stromal thickness did not differ significantly between any of
the CXL groups.
Time Taken for Complete Digestion
Stromal swelling, in a posterior–anterior direction was
observed in all corneal disks within 1 day of submersion in
pepsin digest solution (Fig. 2). After 2 days of digestion, a loss
of structural integrity was seen in the untreated corneas but
the crosslinked corneas remained intact (Fig. 2). By day 7 of
the digestion process, the anterior portion of each treated and
untreated corneal button had separated from the posterior
portion and by day 10, the posterior portion had been
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completely digested in all cases. The anterior corneal disk
persisted considerably longer (particularly in the CXL-treated
corneas) and maintained its form sufficiently to allow reliable
measurements of corneal disk diameter to be recorded daily.
The time required for complete digestion of the crosslinked
corneas (groups 3–6) was significantly longer than that
required for the nonirradiated specimens (groups 1 and 2; P
< 0.0001; Fig. 3). After 13 days of digestion, all nonirradiated
corneas had undergone complete digestion and the average
diameter of all the crosslinked corneal disks had decreased in
diameter from their original value.
Corneas crosslinked with higher energy dose treatments
(7.2 J/cm2) using continuous (group 5) or pulsed (group 6)
light took significantly longer to digest than corneas cross-
linked using lower (5.4J/cm2) energy dose treatments (groups
3 and 4; P < 0.0001). A direct comparison between treatments
using the same energy dose revealed that corneas crosslinked
using the SCXL (5.4 J/cm2) procedure took longer to digest
than corneas crosslinked using the accelerated HCXL (5.4 J/
cm2) procedure (P < 0.0001), and corneas crosslinked using
the pulsed irradiation p-HCXL (7.2 J/cm2) procedure took
significantly longer to digest than those treated with the
continuous irradiation HCXL (7.2J/cm2) procedure (P <
0.0001).
Undigested Tissue Mass
After 13 days in pepsin digest solution, only the CXL-treated
corneas remained (Fig. 4). At this time point, the average
stromal dry weight of the SCXL (5.4 J/cm2)–treated corneas
was significantly higher than that of the HCXL 5.4 J/cm2– (P <
0.0001), HCXL 7.2 J/cm2– (P < 0.001), and p-HCXL 7.2J/cm2–
treated corneas (P < 0.05). The stromal dry weight did not
differ significantly between the two higher energy treatment
groups which used continuous (HCXL 7.2 J/cm2) and pulsed
(p-HCXL 7.2 J/cm2) irradiation, but the corneas treated with p-
HCXL 7.2 J/cm2 had a higher stromal dry weight than the
corneas treated with HCXL 5.4 J/cm2 (P < 0.0001).
DISCUSSION
Crosslinking has been shown to be a safe and effective
treatment for keratoconus7–10 and other corneal ectatic
disorders.23,24 The efficacy of CXL can be attributed, at least
in part, to its ability to increase the enzymatic resistance of
corneal tissue, as enzymatic digestion is known to be involved
in the pathogenesis of keratoconus.25
An increase in enzymatic resistance following CXL with
irradiances of 2 and 3 mW/cm2 UVA was first evidenced by
Spoerl et al.22 and later by others.21 It since has been shown
that the use of CXL with irradiances of 9 and 18 mW/cm2 also
results in enhanced enzymatic resistance.26 However measure-
ments of undigested tissue mass midway through the digestion
process revealed significant differences between treatment
groups that indicated that the amount of CXL may be less when
higher intensity ‘‘accelerated’’ protocols, with the same
cumulative dose as SCXL, are used.26 While some studies
show little differences between SCXL and accelerated CXL, a
possible reduction in efficacy with high-intensity UVA proto-
cols has been documented recently by some clinical investi-
gators. Ng et al.27 compared 9 mW/cm2 for 10 minutes to
SCXL and reported a statistically greater reduction in maximum
and mean keratometry and deeper demarcation lines in SCXL-
treated eyes.27 Similar results were reported in a retrospective
study by Brittingham et al.14
Oxygen is essential to drive the riboflavin/UVA CXL process
and in its absence crosslink formation is impaired.13 It has been
postulated that reduced efficacy with accelerated CXL
protocols is due to more rapid oxygen depletion compared
to the more prolonged but less intense UVA exposure in
SCXL.14,15 As oxygen can be restored to its normal tissue levels
FIGURE 1. Average corneal thickness measured before, during, and after treatment.
FIGURE 2. Photographs of a representative corneal disk from each
treatment group before immersion in pepsin digest solution (day 0) and
after 1 and 2 days of digestion.
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within 3 to 4 minutes of cessation of UVA radiation,16 it has
been postulated that by pulsing the UV light, oxygen levels
may be replenished so that the CXL process is no longer
impaired.17,18 In addition to pulsing, some investigators have
demonstrated that the efficacy of accelerated CXL protocols
may be improved by increasing the UVA exposure time, and,
hence, the overall cumulative dosage, by 30% to 40%.19,20 In
this present study, we tested a number of these newer
commercially available extended and pulsed accelerated
protocols by investigating their resistance to enzymatic
(pepsin) digestion.
All eyes treated in our study received an application of an
isoosmolar riboflavin solution (containing 20% dextran) to the
deepithelialized corneal surface. Consistent with previous
studies,21,28 this resulted in a significant decrease in corneal
thickness. The corneal thinning can be attributed primarily to
the deturgescent effect of the dextran but also, possibly, to the
presence of riboflavin,26 which has the effect of increasing the
ionic strength of the applied solution and presumably further
lowering the hydration of the cornea.29
Due to treatment-induced variations in corneal thickness
and the swelling of the trephined corneal disks (in the
posterior-anterior direction) during the first 24 hours of
immersion in pepsin digest solution,26 corneal thickness
measurements were considered to be an unreliable measure
of the rate of enzymatic digestion. Instead, in this current
study, daily measurement of the diameter of the anterior
corneal surface and the dry weight of the undigested tissue
after 13 days of digestion was performed. These measurements
provided a more accurate assessment of the structural integrity
of the anterior corneal stroma and the effective depth of CXL
following each treatment variation.
The discovery that corneas treated with HCXL (5.4 J/cm2)
had a lower residual mass after 13 days of digestion, and took
less time to undergo complete digestion than SCXL-treated
corneas, suggests a reduced CXL effect and a failure of the
Bunsen–Roscoe law of reciprocity at higher UVA intensities.
This supports the findings of biomechanical studies which
have reported a reduced corneal stiffening effect with
increasing UVA intensity up to 18mW,30 and a sudden decrease
in efficacy with very high intensities greater than 45 mW/
cm2.31 The failure of the Bunsen-Roscoe law of reciprocity in
cases of very high intensity and short illumination time is not
yet fully understood, but is thought to be caused, as discussed
above, by insufficient oxygen availability inhibiting the CXL
process.13 This hypothesis is supported by our findings of
increased enzymatic resistance in p-HCXL treated eyes, where
oxygen availability theoretically should be greater than in the
nonpulsed HCXL treatments.
The precise photochemical mechanisms involved in ribo-
flavin/UVA CXL are unknown. It has been postulated that the
process commences under aerobic conditions with a brief type
II photochemical reaction, in which sensitized photooxidation
of stromal proteins occurs, mainly by their reaction with
photochemically generated reactive oxygen species.16 As
oxygen becomes depleted, after the initial 15 seconds of
exposure to UVA, a type I photosensitizing mechanism then
may predominate, in which radical ions are produced that can
induce covalent CXL of stromal macromolecules.16 In SCXL,
where UVA exposure occurs over 30 minutes, the oxygen
FIGURE 3. The summed diameter of all corneal disks (n¼ 6) within each crosslinked and noncrosslinked treatment group is shown as a function of
time in pepsin digest solution. In addition, the average time (6SD) required for complete digestion of each treatment group has been added to the
time-line.
FIGURE 4. Corneal disk dry weight after 13 days of digestion.
Corneal Enzymatic Resistance Following Crosslinking IOVS j April 2016 j Vol. 57 j No. 4 j 1550
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/935164/ on 04/26/2016
concentration in the cornea may slowly increase, during the
later stages of the treatment, to a level at which a type-II
mechanism may once again begin.16
The enhanced enzymatic resistance we observed when the
exposure time of the cornea to 30 mW UVA was increased
from 3 to 4 minutes may be attributed to the increase in the
total energy dose from 5.4 to 7.2 J/cm2, which allowed
additional type I photochemical CXL to occur. It is unlikely that
the increased CXL effect is due to the extended treatment
providing additional time for the oxygen levels to be
replenished to a level at which the type II CXL reaction could
be restarted as, even when SCXL is performed, the oxygen
concentration is thought only to reach sufficient levels in the
latter half of the 30-minute treatment.16
Although corneas treated with HCXL and p-HCXL and a
total energy dose of 7.2 J/cm2 persisted longer in enzyme
digest solution than SCXL (5.4J/cm2)–treated corneas, the dry
weight of the SCXL-treated corneas was higher when measured
midway through the digestion process. This suggested that
differences in the distribution of CXL may exist within the
tissue. It can be postulated that CXL using a higher UVA
intensity and a greater total energy dose results in superior CXL
efficacy within the most anterior stromal layers and/or the mid-
corneal region, resulting in longer overall digestion times.
However, the depth of CXL may be shallower or there may be a
more rapid decrease in the intensity of CXL as a function of
depth, compared to SCXL, resulting in a reduced overall mass
of crosslinked tissue. It is of interest that Brillouin microscopy
studies of SCXL-treated corneas have shown that the intensity
of CXL is depth-dependent, with the anterior stroma contrib-
uting the most to the increase in mechanical stiffness, and
examination of the effect of varying UVA exposure time (0–30
minutes) has shown a dose-dependent tissue stiffening in the
anterior third of the cornea.32
The clinical relevance of these findings is uncertain, as the
precise amount and location of crosslinked tissue required to
prevent keratoconic progression has yet to be determined.
Clinical studies comparing CXL with accelerated CXL proto-
cols are limited and somewhat conflicting. Tomita et al.,33 in a
study comparing SCXL with 30 mW/cm2 for 3 minutes, found
no differences in visual and topographic indices and similar
demarcation line depths at 6 months, while Shetty et al.,34 in a
randomized clinical study in 138 eyes with 12-month follow-
up, found poorer refractive and tomographic outcomes with
30 mW/cm2 for 3 minutes. A small clinical trial involving 20
patients treated with either pulsed or continuous light HCXL
showed keratoconus stability in both groups at 1 year follow-
up, although the pulsed light treatment produced better
functional outcomes and a deeper stromal penetration.17
Similarly, a retrospective assessment of 60 patients treated
with HCXL found the demarcation line to be significantly
deeper in patients treated with pulsed rather than continuous
light.35 Clearly further, comparative clinical studies are
required especially comparing the outcomes of p-HCXL with
standard CXL, both of which appeared on this basis of this
study to offer the best outcomes in terms of resistance to
enzyme digestion.
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